| Strategies for therapy of retinal diseases using systemic drug delivery: relevance of transporters at the blood-retinal barrier. | |
| | |
MedLine Citation:
|
PMID: 22035231 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
There is an increasing need for managing rapidly progressing retinal diseases because of the potential loss of vision. Although systemic drug administration is one possible route for treating retinal diseases, retinal transfer of therapeutic drugs from the circulating blood is strictly regulated by the blood-retinal barrier (BRB). AREAS COVERED: This review discusses the constraints and challenges of drug delivery to the retina. In addition, this article discusses the properties of drugs and the conditions of the BRB that affect drug permeability. The reader will gain insights into the strategies for developing therapeutic drugs that are able to cross the BRB for treating retinal diseases. Further, the reader will gain insights into the role of BRB physiology including barrier functions, and the effect of influx and efflux transporters on retinal drug delivery. EXPERT OPINION: When designing and selecting optimal drug candidates, it's important to consider the fact that they should be recognized by influx transporters and that efflux transporters at the BRB should be avoided. Although lipophilic cationic drugs are known to be transported to the brain across the blood-brain barrier, verapamil transport to the retina is substantially higher than to the brain. Therefore, lipophilic cationic drugs do have a great ability to increase influx transport across the BRB. |
| | |
Authors:
|
Ken-ichi Hosoya; Masatoshi Tomi; Masanori Tachikawa |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2011-10-29 |
Journal Detail:
|
Title: Expert opinion on drug delivery Volume: 8 ISSN: 1744-7593 ISO Abbreviation: Expert Opin Drug Deliv Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-11-21 Completed Date: 2012-03-08 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 101228421 Medline TA: Expert Opin Drug Deliv Country: England |
Other Details:
|
Languages: eng Pagination: 1571-87 Citation Subset: IM |
Affiliation:
|
University of Toyama, Graduate School of Medicine and Pharmaceutical Sciences, Department of Pharmaceutics, 2630, Sugitani, Toyama 930 0194, Japan. hosoyak@pha.u-toyama.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Blood-Retinal Barrier / metabolism* Drug Administration Routes Humans Hydrophobic and Hydrophilic Interactions Membrane Transport Proteins / metabolism* Permeability Retinal Diseases / drug therapy*, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Membrane Transport Proteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Qualitative determination of carbon black in food products.
Next Document: A Facile Vapor Phase Hydrothermal Method for Direct Growth of Titanate Nanotubes on Titanium Substra...